Chief Business Development Officer

Annie Chang

“Sutro’s accomplishments is a testament to the strength of Sutro’s capabilities, which I believe offers a completely unique approach to developing ADCs and other therapies that can meaningfully improve patient care.”

Dr. Leyman joined Sutro in 2024 and she brought 20 years of deal making experience in life sciences to the company. Prior to Sutro, she worked at GenEdit, where she oversaw business development, alliance management and corporate strategy. At GenEdit, she successfully led the business development efforts towards the execution of the multiyear collaboration and license agreement with Genentech for a total deal value of $644M. Prior to joining GenEdit, she held positions of increasing responsibility in business development and corporate strategy at Lyell Immunopharma and Calico Life Sciences. In those positions, she led licensing, R&D collaborations and co-development transactions through due diligence, negotiation and execution. She obtained the best performance award of 2020 at Lyell Immunopharma. 

Prior to joining industry, she led the life sciences team at LRM, a venture capital fund, where she managed investment transactions in biotech companies and was a director on the board of 3 biotech companies (Apitope, Amakem and Complix). She started her business career as Licensing and New Ventures Manager at the Flanders Institute for Biotechnology (VIB), a biotech translational research institute. Dr. Leyman is trained as a molecular biology scientist and published a first author manuscript in Science. She obtained a PhD in Molecular Biology from Imperial College at Wye, London University, UK and a Master’s degree in Chemistry and Biotechnology from Ghent University, Belgium.